Cancer Stem Cell News Volume 9.31 | Aug 19 2020

    0
    34







    2020-08-19 | CSCN 9.31


    Cancer Stem Cell News by STEMCELL Technologies
    Vol. 9.31 – 19 August, 2020
    TOP STORY

    OSMR
    Controls Glioma Stem Cell Respiration and Confers Resistance of Glioblastoma to Ionizing Radiation

    The authors report the discovery of a mitochondrial oncostatin M that conferred resistance to ionizing radiation via regulation of oxidative phosphorylation, independent of its role in cell proliferation.
    [Nature Communications]

    Full Article


    Resources for Your T Cell Therapy Research
    PUBLICATIONSRanked by the impact factor of the journal

    Photothermogenetic
    Inhibition of Cancer Stemness by Near-Infrared-Light-Activatable Nanocomplexes

    A combination of nanomaterial design and genetic engineering effectively eliminated cancer cells and suppressed stemness of cancer cells in vitro and in vivo.
    [Nature Communications]

    Full Article

    DAXX-Inducing Phytoestrogens Inhibit ER+
    Tumor Initiating Cells and Delay Tumor Development

    Investigators aimed to identify a death-associated factor 6 (DAXX)-inducing agent to inhibit tumor initiating cells and prevent proliferation of the tumor.
    [npj Breast Cancer]

    Full Article

    Tumor
    Suppressor 15-Hydroxyprostaglandin Dehydrogenase Induces Differentiation in Colon Cancer via GLI1 Inhibition

    Leukotriene C4-mediated reduction in the DCLK1 and LGR5 stemness markers in colonospheres was abolished in cells lacking 15-hydroxyprostaglandin dehydrogenase or GLI1.
    [Oncogenesis]

    Full Article

    PD-L1+
    Lung Cancer Stem Cells Modify the Metastatic Lymph-Node Immunomicroenvironment in NSCLC Patients

    Scientists investigated correlations between PD-L1+ cancer stem cells, changes in T-cell phenotype in metastatic and non-metastatic lymph nodes and response to treatment.
    [Cancer Immunology Immunotherapy]

    Full Article

    STAT3
    Inhibition with Galiellalactone Effectively Targets the Prostate Cancer Stem-Like Cell Population

    Researchers investigated the effect of galiellalactone, a direct STAT3 inhibitor, on CSCs derived from prostate cancer patients, on docetaxel-resistant spheres with stem cell characteristics, on CSCs obtained from the DU145 cell line in vitro and on DU145 tumors in vivo.
    [Scientific Reports]

    Full Article

    Flavagline
    Synthetic Derivative Induces Senescence in Glioblastoma Cancer Cells without Being Toxic to Healthy Astrocytes

    Investigators explored the effect of FL3 in glioblastoma cells under normoxia and hypoxia conditions. They indicated that this synthetic flavagline inhibits cell proliferation and induced senescence in glioblastoma cells cultured under both conditions.
    [Scientific Reports]

    Full Article

    In Vitro
    Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features

    Researchers compared the effects of tyrosine kinase inhibitors belonging to different generations, imatinib and ponatinib, on progenitor/stem cell expansion potential and markers.
    [Targeted Oncology]

    Full Article

    Tunneling
    Nanotubes Mediate Adaptation of Glioblastoma Cells to Temozolomide and Ionizing Radiation Treatment

    The authors showed that heterogeneous glioblastoma cells expressed TNTs upon oxidative stress and temozolomide/ionizing radiation treatment.
    [iScience]

    AbstractFull Article
    Graphical Abstract

    2-Nitroimidazoles
    Induce Mitochondrial Stress and Ferroptosis in Glioma Stem Cells Residing in a Hypoxic Niche

    Investigators showed that the 2-nitroimidazole doranidazole potentiated radiation-induced DNA damage in hypoxic glioma stem cells (GSCs) and conferred a significant survival benefit in mice harboring GSC-derived tumors in radiotherapy settings.
    [Communications Biology]

    Full Article


    Scientific resources to support your cancer research. Learn More!
    REVIEWS

    The
    MAPK and AMPK Signalings: Interplay and Implication in Targeted Cancer Therapy

    The authors summarize the current proceedings of how MAPK-AMPK signalings interplay with each other in cancer biology, as well as its implications in clinic cancer treatment with MAPK inhibition and AMPK modulators, and discuss the exploitation of combinatory therapies targeting both MAPK and AMPK as a novel therapeutic intervention.
    [Journal of Hematology & Oncology]

    Full Article

    Differentiation
    of Cancer Stem Cells Using Synthetic Small Molecules: Toward New Therapeutic Strategies against Therapy Resistance

    Several strategies have been proposed to specifically target CSCs such as the use of CSC‐specific antibodies, small molecules able to target CSCs signaling pathways or drugs able to induce CSCs differentiation rendering them sensitive to classical chemotherapy. These latter compounds are the focus of the present review that aims at reporting recent advances in anticancer differentiation strategy.
    [ChemMedChem]

    Abstract

    INDUSTRY AND POLICY NEWS

    ERC
    Announces Interim Results from Phase II Trial of Immunotherapy ERC1671 in Recurrent Glioblastoma Patients

    ERC Belgium announced promising interim results in the Phase II clinical trial for ERC1671 under FDA IND 15430 at the University of California, Irvine Medical Center.
    [ERC Belgium (Business Wire, Inc.)]

    Press Release

    Australian
    Therapeutic Goods Administration (TGA) Approves the First Phase I Trial of ATG-017 (ERK 1/2 Inhibitor) for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

    Antengene Corporation announced the authorization of the first-in-human trial of ATG-017 by the Australian Therapeutic Goods Administration. ATG-017 is a potent and selective small molecule extracellular signal–regulated kinases 1 and 2 inhibitor.
    [Antengene Corporation]

    Press Release

    FEATURED EVENT

    NCRI 2020: Virtual Showcase

    November 2 – November 3
    Virtual


    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Associate – RNA Epigenetics in Cancer Stem Cells

    Sanford Burnham Prebys Medical Discovery Institute – La Jolla, California, United States

    Faculty Position – Prostate Cancer Biology and Cancer Epigenetics

    Northwestern University – Chicago, Illinois, United States

    Postdoctoral Fellowship – Hematopoiesis, Leukemia, and Bone Marrow Failure Syndromes

    The University of Texas Southwestern Medical Center – Dallas, Texas, United States


    Postdoctoral Research Fellow – Hematopoiesis, Marrow Failure and Myeloid Leukemia

    Cincinnati Children’s Hospital Medical Center – Cincinnati, Ohio, United States

    Postdoctoral
    Positions – Cancer Epigenomics

    West Virginia University – Morgantown, West Virginia, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Science News Cancer Stem Cell News
    Archives Contact Us
    Cancer Stem Cell News Twitter